<DOC>
	<DOCNO>NCT01830465</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety combination Velcade Rituximab patient relapse Non Hodgkin 's Follicular Lymphoma .</brief_summary>
	<brief_title>VELCADE® Plus Rituximab Non Hodgkin 's Follicular Lymphoma</brief_title>
	<detailed_description>Eligible patient receive combination Velcade-rituximab total 6 cycle Velcade 6 infusion rituximab . Patients evaluate clinical , laboratory , image parameter baseline , study treatment , end treatment follow ( every 6 month 3 year ) . In first stage , 17 patient treat . An interim analysis perform recruitment first 17 evaluable patient . Aim analysis determine preliminary activity treatment.If &gt; 7 response observe , accrual continue 24 additional patient treat total 41 . If ≤ 21 respond , treatment reject ineffective . If 22 respond , treatment judge promising development .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : diagnosis relapse progressed disease pretreated three prior chemotherapy regimen and/or immunochemotherapy ; age &gt; 18 year ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; evidence transformation high grade lymphoma ; active disease require treatment ; twodimensionally measurable disease least one site evaluable disease ; Velcade® naïve ; life expectancy &gt; 6 month ; prior chemotherapy , immunotherapy radiotherapy last 8 week ; adequate renal function ( calculate measure creatinine clearance &gt; 30 mL/minute ) , liver function aspartate aminotransferase ( ASAT ) /alanine aminotransferase ( ALAT ) &lt; 3.0 x upper normal , total bilirubin &lt; 2,5 x upper normal ) , unless due lymphoma involvement ; leave ventricular ejection fraction ( LVEF ) &gt; 50 % ; evidence active opportunistic infection ; HbsAg , hepatitis C virus ( HCV ) e HIV negativity . Positive serology hepatitis B virus ( HBV ) HCV admit upon negativity HBVDNA HCVRNA test ; serious medical illness likely interfere participation clinically study ; voluntary Written Informed Consent performance studyrelated procedure ; patient able ( i.e . sufficiently fluent ) willing complete quality life questionnaire validate translation . Inability ( illiteracy , loss sight , equivalent reason ) complete questionnaire make patient ineligible study . However , ability unwillingness complete questionnaire make patient ineligible ; 17. female subject either postmenopausal surgically sterilize willing use acceptable method birth control ( ie , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study ; prior diagnosis neoplasm ( except follicular lymphoma ) within 5 year , except cervical intraepithelial neoplasia type 1 ( CIN1 ) localize non melanomatous skin cancer ; refractory disease ( non respond patient previous treatment ) ; investigational drug within 28 day enrollment ; evidence symptomatic central nervous system ( CNS ) disease ; severe impairment bone marrow function ( Absolute Neutrophil Count ( ANC ) &lt; 1.5 x 109/L , platelet ( PLT ) &lt; 50 x109/L within 14 day enrollment ) , unless due lymphoma involvement ; evidence ≥ grade 2 neuropathy within 14 day enrollment ; know hypersensitivity bortezomib , boron mannitol ; know hypersensitivity anaphylactic reaction murine antibody protein ; uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure ( Attachment 7 , NYHA Classification Cardiac Disease ) , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis ; pregnant lactating status , confirmation subject pregnant must establish negative serum human chorionic gonadotropin ( hCG ) pregnancy test result obtain screening . Pregnancy test require post menopausal surgically sterilized woman ; psychological , familial , sociological geographical condition potentially hamper compliance study protocol follow schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Non Hodgkin 's Follicular Lymphoma</keyword>
	<keyword>relapse</keyword>
	<keyword>progress</keyword>
</DOC>